Lewis J Stuart
CIK 1407368 · Chief Commercial Officer · last filed 2023-01-27
Lewis J Stuart is a Chief Commercial Officer who has filed 23 SEC Form 4 insider transactions across 3 companies since 2007. Across all open-market trades the lifetime net is −$91.9K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CVTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Chief Commercial Officer | — | $32.48 | — | $0 | 3 | 2023-01-27 |
| Stablecoin Development Corp (NBY) Delisted | Chief Commercial Officer | — | $1.95 | — | $0 | 2 | 2018-01-08 |
| CV THERAPEUTICS INC (CVTX) Delisted | SVP COMMERCIAL OPERATIONS | 63,777 | — | — | -$91.9K | 12 | 2009-04-17 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-06 | — | Notice (144) | −30,620 | -$733.3K | EDGAR |
| 2024-01-22 | — | Notice (144) | −62,257 | -$1.53M | EDGAR |
| 2024-01-19 | — | Notice (144) | −50,000 | -$1.17M | EDGAR |
| 2024-01-18 | — | Notice (144) | −60,749 | -$1.42M | EDGAR |
| 2024-01-17 | — | Notice (144) | −40,158 | -$939.7K | EDGAR |
| 2024-01-03 | — | Notice (144) | −337,583 | -$8.19M | EDGAR |
| 2023-01-27 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-27 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-10 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-08 | Stablecoin Development Corp (NBY) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.